Activist pressure meets stable prices and new regulatory risks
- In Q2 2026, Clear Aligner revenue grew 8.2% to $870.9 million, making up 82% of total revenue.
- Case volume rose 7.4%, and average selling price increased 0.8% to $1,260 per case.
- Systems and Services revenue dropped 10.8% to $185.3 million due to a shift toward scanner leases.
- Activist investor Elliott Management sparked a strategic review and a new stock buyback plan.
- The European Commission launched a formal antitrust probe regarding aligners and scanners in the EEA.
- A new 20% U.K. tax ruling creates a headwind for European sales starting in September 2026.
Pricing holds as activists step in
Align's core story took a sharp turn in the summer of 2026. Activist investor Elliott Management is now involved, pushing the company to start a comprehensive strategic review and expand share repurchases. At the same time, Q2 2026 proved that the previous quarter's pricing stability was not a fluke. Clear Aligner volume rose 7.4% and the average selling price held steady at $1,260.
The bull case focuses on this solid foundation. If Invisalign pricing remains stable, the company can grow margins without sacrificing volume. The shift to leasing iTero scanners hurts upfront revenue but successfully expanded the active scanner base by 11%. More scanners in dental offices means more future Invisalign cases. To support this growth, Align is building a new facility in India set to open in 2027.
The bear case points to structural weakness in the equipment market and mounting regulatory headaches. Systems and Services revenue fell 10.8% year over year in Q2 2026. Dentists are clearly cautious about buying expensive equipment outright. Furthermore, a formal antitrust investigation by the European Commission and a new 20% value-added tax in the U.K. create massive regional hurdles.
Finn's view is that the activist involvement provides a strong floor for the stock. However, growth will remain lumpy until the European regulatory impact is understood and the scanner leasing strategy proves it can generate sustainable recurring revenue.
Selling cases, leasing scanners
Align makes most of its money by selling Invisalign treatment packages directly to orthodontists and general dentists. The dentist buys the case from Align, then treats the patient. Align also sells retainers, training, and other non-case products tied to clear aligner treatment.
The second business provides iTero intraoral scanners and exocad software used by dental labs. A scanner replaces a messy physical mold with a digital scan of the mouth. Historically, Align sold these machines upfront. Now, the company is shifting to leasing and rental programs. This lowers immediate revenue but makes it cheaper for dentists to adopt the technology.
The model works best when the two parts feed each other. A dentist who leases an iTero scanner is more likely to send Invisalign cases to Align. That creates a sticky digital system.
Where it breaks is price pressure. Clear aligners face heavy competition. If dentists or patients push for cheaper options, Align has to offer discounts. That hurts revenue per case and squeezes margins.
The dental stack
Invisalign system
This is Align's main product line. It includes clear aligner treatment packages such as Comprehensive, Moderate, Lite, Express, and First.
Vivera retainers
Vivera retainers help patients keep their teeth in place after treatment. They add repeat revenue tied to the Invisalign base.
iTero scanners
iTero scanners take digital 3D scans of the mouth. The company is actively pushing lease and rental models to grow the installed base.
Align and iTero software
Tools like Align Oral Health Suite and iTero Design Suite help dentists plan, show, and manage care.
exocad CAD/CAM software
exocad serves dental labs and supports digital design and manufacturing workflows. It gives Align a wider role in dental work beyond clear aligners.
Cubicure direct 3D printing
Align bought Cubicure in 2024 for proprietary direct 3D printing technology. The goal is to eventually make devices without first creating molds.
Still an Invisalign company
Segment mix is from Q2 2026 revenue. Clear Aligner makes up about 82% of revenue, meaning volume and pricing in Invisalign still dictate company performance.
What could break the recovery
European antitrust probe
High impact · Medium oddsThe European Commission launched a formal antitrust investigation in June 2026. Regulators are checking if Align abused a dominant market position with its clear aligners and scanners. This could lead to massive fines or forced changes to how the company operates in Europe.
New U.K. tax burden
Medium impact · High oddsA U.K. tribunal ruled that clear aligners are not exempt from value-added taxes. Starting September 2026, a 20% tax will be added to U.K. invoices. This will make Invisalign much more expensive for patients and could crush volume in a key market.
Scanner revenue decline
Medium impact · High oddsSystems and Services revenue fell nearly 11% in Q2 2026. The company is pushing dentists to lease scanners instead of buying them. If those leased scanners do not translate into higher Invisalign case volumes, Align simply traded high upfront cash for a weak rental stream.
ASP slide returns
High impact · Medium oddsAverage selling price stabilized in early 2026, hitting $1,260 per case. If discounts, cheaper product mix, or currency issues push ASP down again, volume growth will not turn into better profits.
Geopolitical and manufacturing shocks
Medium impact · Medium oddsAlign has iTero operations headquartered in Israel and manufacturing exposure in Mexico. A supply disruption could hurt scanner supply, aligner production, or raise freight costs.
In one breath
How does Align Technology make money?
Align mainly sells Invisalign clear aligner cases to orthodontists and dentists. It also sells or leases iTero scanners, scanner software, disposables, retainers, and dental lab software.
Why does average selling price matter so much for ALGN?
Average selling price shows how much Align earns per clear aligner case. In 2025, volume grew while price fell, which hurt margins. In 2026, price finally stabilized, lifting profits.
Why is activist investor Elliott Management involved?
Elliott Management stepped in to push for better commercial execution and capital allocation. This led to a strategic review of the operating model and a larger share buyback plan.
What should investors watch next?
Watch the outcome of the European antitrust investigation, Clear Aligner ASP, and U.K. case volume after the new 20% tax takes effect in September 2026.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- September 13, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
Comparable Medical Instruments & Supplies companies
Companies near Align Technology, Inc. in Finn's Medical Instruments & Supplies industry ranking.
